Intravesical Epirubicin Versus Doxorubicin for Superficial Bladder Tumors (Stages pTa and pT1): a Randomized Prospective Study

Ali-El-Dein, Bedeir; El‐Baz, Mahmoud; Nabeeh, Adel; Shamaa, Sameh; Ashamallah, Albair

doi:10.1097/00005392-199707000-00018

Cited by 53 publications

(21 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other studies did not find a difference in efficacy between different drug concentrations [31][32][33][34]36]. Weekly instillations during 5 mo appear to be as effective as long-term instillations during 3 yr, which were given less frequently during the initial 5-mo period [26,27].…”

Section: Discussionmentioning

confidence: 85%

“…No difference in efficacy was found between the two doses for either 4 wk or 2 yr of treatment. When 18 instillations of epirubicin were given within 1 yr, there was no difference between 50 mg/50 ml (900 mg) and 80 mg/50 ml (1440 mg) in the percentage who had recurrence, 25.0% versus 17.6%, respectively [33]. Likewise, there was no difference in efficacy in a trial comparing 30 mg/30 ml to 60 mg/60 ml of thiotepa where instillations were given every 4 wk for a maximum of 2 yr [34].…”

Section: Two Years Of Chemotherapy-two Trials Compared Weekly Instillmentioning

confidence: 90%

“…Other studies did not, however, find a difference in efficacy between different drug concentrations [31][32][33][34]. Two concentrations of Adriamycin, 20 mg/40 ml and 30 mg/30 ml, were compared using two different treatment schedules: 8 instillations within 4 wk (160 mg vs. 240 mg) or 21 instillations within 2 yr (420 mg vs. 630 mg) [31,32].…”

Section: Two Years Of Chemotherapy-two Trials Compared Weekly Instillmentioning

confidence: 99%

See 2 more Smart Citations

The Schedule and Duration of Intravesical Chemotherapy in Patients with Non–Muscle-Invasive Bladder Cancer: A Systematic Review of the Published Results of Randomized Clinical Trials

2008

View full text Add to dashboard Cite

Objectives-Intravesical chemotherapy has been studied in randomized clinical trials for >30 yr; however, the optimal schedule and duration of treatment are unknown. The objective is to determine the effect of schedule and duration of intravesical chemotherapy on recurrence in patients with stage Ta T1 bladder cancer.Methods-A systematic review was conducted of the published results of randomized clinical trials that compared intravesical instillations with respect to their number, frequency, timing, duration, dose, or dose intensity.

show abstract

Section: Discussionmentioning

confidence: 85%

Section: Two Years Of Chemotherapy-two Trials Compared Weekly Instillmentioning

confidence: 90%

Section: Two Years Of Chemotherapy-two Trials Compared Weekly Instillmentioning

confidence: 99%

See 1 more Smart Citation

The Schedule and Duration of Intravesical Chemotherapy in Patients with Non–Muscle-Invasive Bladder Cancer: A Systematic Review of the Published Results of Randomized Clinical Trials

2008

View full text Add to dashboard Cite

show abstract

“…17 Multivariate analysis from other studies has identified several risk factors for poor prognosis for Stage pTa-pT1 bladder cancer, including stage, grade, tumor multiplicity, tumor size, association with CIS, previous recurrence, and results of the 3-month cystoscopy. [2][3][4][5][6][7][8][9][10][11] These studies have also shown that lamina propria invasion is 1 of the most important prognostic indicators. All these studies have presented global information on patients with non-muscle invasive bladder cancer: both Ta and T1 tumors were included, and the tumor grades ranged from 1 to 3.…”

Section: Commentmentioning

confidence: 99%

“…1 Much research on Stage T1 tumors of the bladder has been devoted to the identification of risk factors for recurrence and progression. [2][3][4][5][6][7][8][9][10][11] Heney 12 stated that, "in T1 tumors the individual course is difficult to predict, especially in grade 2 (WHO [World Health Organization] 1973) disease. "…”

mentioning

confidence: 99%

Recurrence at Three Months and High-grade Recurrence as Prognostic Factor of Progression in Multivariate Analysis of T1G2 Bladder Tumors

Palou

Rodríguez-Rubio

Millán

et al. 2009

Urology

View full text Add to dashboard Cite

OBJECTIVESTo evaluate the risk factors for disease progression in the frequent subgroup of Stage T1G2 (World Health Organization 1973) bladder tumors using an analysis of a large cohort of patients with Stage T1G2 disease. METHODSA cohort of 616 patients with Stage T1G2 were treated with transurethral resection and random bladder biopsies. The mean follow-up was 4.2 years. Univariate and multivariate analyses were done using Cox regression analysis. The independent variables were multiplicity, association with carcinoma in situ (CIS), tumor size, tumor recurrence at 3 or 6 months, tumor grade, and association with CIS at first recurrence. The dependent variable was progression to muscleinvasive disease. RESULTSProgression to muscle-invasive disease was identified in 28 of the 616 patients (4.5%). On multivariate analysis, when considering recurrence at 3 months, this factor was the principal prognostic factor, with a relative risk of 4.0 (95% confidence interval 1.2-13.3), followed by the presence of high-grade disease or CIS at first recurrence (relative risk 2.8, 95% confidence interval 1.3-5.8) and CIS associated with the primary tumor (relative risk 1.8, 95% confidence interval 1.1-2.9). When considering recurrence at 6 months, more prognostic factors were involved for progression, including as multiple tumors, CIS associated with the primary tumor, recurrence at 6 months, and the presence of high-grade disease or CIS at the first recurrence. CONCLUSIONSIn primary urothelial T1G2 bladder cancer, recurrence at 3 months was the main prognostic factor related to progression. Additional factors were the association of CIS with the primary tumor and the presence of high-grade disease and/or CIS at first recurrence. UROLOGY 73: 1313UROLOGY 73: -1317UROLOGY 73: , 2009

show abstract

Non–muscle‐invasive bladder cancer: Intravesical treatments beyond Bacille Calmette‐Guérin

Packiam

Johnson

Steinberg

2016

Cancer

View full text Add to dashboard Cite

An unmet need exists for patients with high-risk non-muscle-invasive bladder cancer for whom bacille Calmette-Guérin (BCG) has failed and who seek further bladder-sparing approaches. This shortcoming poses difficult management dilemmas. This review explores previously investigated first-line intravesical therapies and discusses emerging second-line treatments for the heterogeneous group of patients for whom BCG has failed. The myriad of recently published and ongoing trials assessing novel salvage intravesical treatments offer promise to patients who both seek an effective cure and want to avoid radical surgery. However, these trials must carefully be contextualized by specific patient, tumor, and recurrence characteristics. As data continue to accumulate, there will potentially be a role for these agents as second-line or even first-line intravesical therapies. Cancer 2017;123:390-400. © 2016 American Cancer Society.

show abstract

Intravesical Epirubicin Versus Doxorubicin for Superficial Bladder Tumors (Stages pTa and pT1): a Randomized Prospective Study

Abstract: This study demonstrates that epirubicin has better efficacy and lower toxicity than doxorubicin when used as an intravesical agent.

Cited by 53 publications

References 19 publications

The Schedule and Duration of Intravesical Chemotherapy in Patients with Non–Muscle-Invasive Bladder Cancer: A Systematic Review of the Published Results of Randomized Clinical Trials

The Schedule and Duration of Intravesical Chemotherapy in Patients with Non–Muscle-Invasive Bladder Cancer: A Systematic Review of the Published Results of Randomized Clinical Trials

Recurrence at Three Months and High-grade Recurrence as Prognostic Factor of Progression in Multivariate Analysis of T1G2 Bladder Tumors

Non–muscle‐invasive bladder cancer: Intravesical treatments beyond Bacille Calmette‐Guérin

Contact Info

Product

Resources

About